Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs.
Exit since June 2012.
MYR develops a novel, peptide-based, first-in-class drug (entry inhibitor) for the treatment of chronic hepatitis B and Delta infections. Clinical phase IIb currently in preparation.
Provecs Medical Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system.
Exit since July 2015.